Saturday, November 27, 2021
HomeCoronavirus WatchDeveloping neutralising nanobodies against SARS-CoV-2 variants including SA variant — Alpaca preprint

Developing neutralising nanobodies against SARS-CoV-2 variants including SA variant — Alpaca preprint

Study details
Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351

Agnieszka M Sziemel, Shi-Hsia Hwa, Alex Sigal, Grace Tyson, Nicola Logan, Brian J Willett, Peter J Durcan

Published in bioRxiv on 12 April 2021

The pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. During the years of 2020-2021, millions of humans have died due to SARS-CoV-2 infection and severe economic damage to the global economy has occurred. Unprecedented rapid investments in vaccine development have been made to counter the spread of SARS-CoV-2 among humans. While vaccines are a key pillar of modern medicine, SARS-CoV-2 has mutated as it spread among humans. Vaccines previously developed and approved by regulators are becoming less effective against new variants. One variant of SARS-CoV-2 known as B.1.351 that was first reported to be present in South Africa significantly reduces the efficacy of vaccines developed to date. Therapeutic options that work against the B.1.351 variant are therefore urgently needed to counteract reduced vaccine efficacy. We present here the discovery of recombinant alpaca antibodies that neutralise live virus of B.1.351 and other SARS-CoV-2 variants potently. The antibodies described here may be a useful tool for clinicians who are treating patients infected with B.1.351 and other SARS-CoV-2 for which there is currently no known highly effective treatment.


bioRxiv study (Open access)

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required